Talphera

Talphera Payables Turnover

The Payables Turnover Ratio of Talphera (TLPH) as of Nov 6, 2026 is 10.03. In the previous year, Payables Turnover Ratio was 4.15 — a change of 141.54% (higher).

Payables Turnover

10.03

YoY

141.54%

Last updated:

Payables Turnover Ratio of Talphera is 2024 10.03 . Payables Turnover Ratio of Talphera was 2023 4.15 . It decreases by 141.54% higher compared to the previous year.

The Talphera Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2017
7.49 USD
Jan 1, 2018
1.92 USD
Jan 1, 2019
3.96 USD
Jan 1, 2020
2.20 USD
Jan 1, 2021
1.42 USD
Jan 1, 2022
1.31 USD
Jan 1, 2023
4.15 USD
Jan 1, 2024
10.03 USD
The Talphera Payables Turnover history
YEARPayables TurnoverYoY
10.03+141.54%
4.15+216.57%
1.31-7.48%
1.42-35.69%
2.20-44.30%
3.96+106.01%
1.92-74.34%
7.49-5.30%
7.90-49.14%
15.54+54.07%
10.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

Payables Turnover Ratio of Talphera is 10.03 in 2024.

Payables Turnover Ratio of Talphera changed from 4.15 to 10.03, representing a 141.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio Talphera since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's Talphera with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Talphera

All Key Metrics — Talphera